(Total Views: 266)
Posted On: 02/24/2021 10:18:20 AM
Post# of 36549
Totally agreed. Reuters just put out on their news feed also the info on GNBT and their complete vaccine....
Feb 24 (Reuters) - Generex Biotechnology Corp(GNBT):
* GENEREX AND NUGENEREX IMMUNO-ONCOLOGY PROVIDE UPDATE ON II-KEY COVID-19 COMPLETE VACCINE™ DEVELOPMENT PROGRAM
* GENEREX BIOTECHNOLOGY(GNBT) - II-KEY-SARS-COV-2 VACCINE GENERATES VACCINE-SPECIFIC ANTIBODIES & T CELL RESPONSES IN A TRANSGENIC MOUSE MODEL
* GENEREX BIOTECHNOLOGY CORP(GNBT) - II-KEY VACCINE ELICITS BOTH CD4+ T HELPER CELL (TH1) AND CD8+ RESPONSES
* GENEREX BIOTECHNOLOGY(GNBT) - INITIATED DISCUSSIONS WITH A MAJOR RESEARCH INSTITUTION ON LICENSING THERAPEUTIC ANTIBODIES AGAINST SARS-COV-2 Source text for Eikon: Further company coverage:
Feb 24 (Reuters) - Generex Biotechnology Corp(GNBT):
* GENEREX AND NUGENEREX IMMUNO-ONCOLOGY PROVIDE UPDATE ON II-KEY COVID-19 COMPLETE VACCINE™ DEVELOPMENT PROGRAM
* GENEREX BIOTECHNOLOGY(GNBT) - II-KEY-SARS-COV-2 VACCINE GENERATES VACCINE-SPECIFIC ANTIBODIES & T CELL RESPONSES IN A TRANSGENIC MOUSE MODEL
* GENEREX BIOTECHNOLOGY CORP(GNBT) - II-KEY VACCINE ELICITS BOTH CD4+ T HELPER CELL (TH1) AND CD8+ RESPONSES
* GENEREX BIOTECHNOLOGY(GNBT) - INITIATED DISCUSSIONS WITH A MAJOR RESEARCH INSTITUTION ON LICENSING THERAPEUTIC ANTIBODIES AGAINST SARS-COV-2 Source text for Eikon: Further company coverage:
(1)
(0)Scroll down for more posts ▼
